Harvard Health, Outcome Health partner with aim to improve digital care

Harvard Health Publications (HHP) and Outcome Health have joined forces to bring Harvard Medical School (HMS)’s insight to 40,000 waiting and exam rooms through Outcome Health’s digital platform.

HHP will bring their healthcare content review and advisory support to Outcome Health’s video and illustrations to offer health services to patients.

“We are excited about this relationship with Outcome Health, which aligns directly with HHP’s mission of improving the health of the nation,” said Gregory Curfman, MD, editor-in-chief of HHP. “We will now be able to create a greater positive impact by sharing Harvard Medical School’s faculty expertise with a broader audience through an engaging and informative experience at the time it matters most: the moments of care.”

Using Outcome Health’s technology platforms such as the Exam Room Tablet, which gives patients easy-to-access lifestyle management programs, and the Digital Wallboard, providing 3D models to use during consultations, providers and patients are able to access information and review records.

“At Outcome Health, we believe that better health outcomes start during the millions of decisions that are made every day in practices, hospitals and health systems,” said Anil Harjani, VP of strategic partnerships at Context Media. “In collaborating with Harvard to bring clinically-validated expertise to patients, caregivers and physicians in the moments of care, we have the opportunity to drive better health decision making at scale—and will use this relationship to continually find compelling and innovative ways to share their insights through our platform.”

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.